Infliximab for treatment of corticosteroid-refractory immune checkpoint inhibitor-induced hepatitis in patients with melanoma
Year: 2025
Type: article
Abstract: Dermatoscopy of a superficial spreading melanoma on the dorsum of the left foot.Results: Patient remained free of disease progression at one year follow-up.Conclusions: Paediatric and adolescent melanomas are very rare with an estimated incidence of one per million in ages up to 14 years old and 71 per million in adolescents [1].Up to today there is only limited information concerning the safety and efficacy of PD-1 checkpoint inhibitors for the treatment of advanced melanoma in these age groups [2].Age specific treatment protocols through multidisciplinary authorities and cohort studies are needed in order to ensure the best possible outcomes for paediatric and young adolescent melanoma patients.1. Indini, A., et al., Incidence and prognosis of cutaneous melanoma in European adolescents and young adults (AYAs): EUROCARE-6 retrospective cohort results.Eur J Cancer, 2024.213: p. 115079.2. Geoerger, B., et al., Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial.Lancet Oncol, 2020.21(1): p. 121-133.
Source: EJC Skin Cancer
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,340
OpenAlex ID: W4409118224